Department of Molecular & Medical Pharmacology and Psychiatry & Behavioral Sciences, University of California, Los Angeles, CA, USA.
Int Rev Neurobiol. 2009;89:147-60. doi: 10.1016/S0074-7742(09)89007-7.
Mutations of MECP2 (methyl-CpG binding protein 2) cause Rett syndrome (RTT). Mouse genetics studies have demonstrated that the lack of functional MeCP2 in the central nervous system leads to RTT-like symptoms, which could be reversed upon MeCP2 restoration. MeCP2 recognizes methylated CpG dinucleotides and may interact with other chromatin remodeling proteins. Although traditionally thought to be a transcription repressor, MeCP2 may also be involved in transcription activation. With the development of new technologies, deciphering the role of MeCP2 on a genome-wide scale is important for understanding of the RTT disease mechanisms.
MECP2(甲基-CpG 结合蛋白 2)突变导致雷特综合征(RTT)。小鼠遗传学研究表明,中枢神经系统中功能性 MeCP2 的缺失会导致类似于 RTT 的症状,而 MeCP2 的恢复可以逆转这些症状。MeCP2 识别甲基化的 CpG 二核苷酸,并可能与其他染色质重塑蛋白相互作用。虽然传统上认为 MeCP2 是转录抑制因子,但它也可能参与转录激活。随着新技术的发展,在全基因组范围内解析 MeCP2 的作用对于理解 RTT 疾病机制非常重要。